Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A phase II trial of the Cytokine Working Group

Journal of Cancer Research and Clinical Oncology

Volumn 128, Issue 4, 2002, Pages 214-218

  Margolin, K ^a   Atkins, M ^b   Thompson, J ^c   Ernstoff, M ^d   Weber, J ^e   Flaherty, L ^f   Clark, J ^g   Weiss, G ^h   Sosman, J ⁱ   Smith, II ^j   Dutcher, J ^k   Gollob, J ^b   Longmate, J ^a   Johnson, D ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

^h University of Texas Health Science Center at San Antonio   (United States)

ⁱ UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^j EARLE A CHILES RESEARCH INSTITUTE   (United States)

^k NEW YORK MEDICAL COLLEGE   (United States)

more..

Author keywords

Brain metastases; Melanoma; Radiation therapy; Temozolomide

Indexed keywords

AMINOTRANSFERASE; DACARBAZINE; TEMOZOLOMIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG SAFETY; FEMALE; HUMAN; MALE; MELANOMA; METASTASIS; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIATION INJURY; SEPSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036208833     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-002-0323-8     Document Type: Article

References (28)

1. Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment, and survival
2. Patterned distribution of metastases from malignant melanoma in humans
3. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation therapy oncology group brain metastases study I and II
4. 6 -alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB10-277, a new DTIC analogue
5. Antitumor imidotetrazines XV. Role of guanine O-6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones
6. 6 -alkylguanine-DNA-alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells
7. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
8. Plasma and cerebrospinal fluid pharmacokinetics of temozolomide
9. Phase I trial of temozolomide
10. Phase I trial of temozolomide in patients with advanced cancer
11. Phase I trial of temozolomide using an extended continuous oral schedule
12. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced, metastatic melanoma
13. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma
14. Daily temozolomide and concomitant radiotherapy followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme: A well tolerated and promising regimen
15. Temozolomide: Drug scheduling in vivo and in combination with radiation
16. Reporting results of cancer treatment
17. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon α-2B in patients with metastatic melanoma
18. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
19. Relapse in the central nervous system in melanoma patients successfully treated with biomodulators
20. Biology of melanoma metastasis
21. Malignant melanoma: Brain metastases: Review of Roswell Park Memorial Institute experience
22. Stereotactic radiosurgery for cerebral metastatic melanoma
23. Brain metastases from malignant melanoma: Conventional vs. high-dose-per fraction radiotherapy
24. Clinical radiobiology of malignant melanoma
25. Radiotherapy of intracerebral metastatic melanoma
26. Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2, and interferon α-2b in patients with metastatic melanoma
27. The chemoresistance of human malignant melanoma: An update
28. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia